相关实验视频
Updated: May 11, 2026

10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
18.5K
探索CLN2临床评分尺度的并发有效性:与PedsQL进行比较,使用cerliponase alfa临床试验数据
Nicola Specchio1, Paul Gissen2, Emily de Los Reyes3
1Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
PloS one
|May 22, 2024
概括
该CLN2临床评分表有效地测量了CLN2疾病的疾病进展,与PedsQL评估的患者生活质量相关,特别是在运动功能方面. 对其他领域可能需要进一步的研究.
科学领域:
- 神经学 神经学
- 罕见疾病 罕见疾病
- 临床治疗学 临床治疗学
背景情况:
- CLN2疾病是一种罕见的,神经退行性疾病,影响儿童.
- 临床评级尺度CLN2评估疾病的进展.
- 这种尺度的验证对于临床试验至关重要.
研究的目的:
- 为了验证CLN2临床评分表.
- 将尺度与儿科生活质量库存 (PedsQL) 进行比较.
- 为了分析CLN2疾病中阿尔法利酶临床试验的数据.
主要方法:
- 使用线性回归和混合效应模型.
- 分析了23名患有CLN2疾病的儿童的数据,这些儿童接受了用cerliponase alfa治疗.
- 包括来自1/2阶段 (NCT01907087) 和延伸研究 (NCT02485899) 的数据.
主要成果:
- 在CLN2临床评分表和PedsQL之间发现了显著的相关性,特别是运动语言得分.
- 物理域显著影响了相关性.
- 在CLN2临床评分表中,运动领域与PedsQL的关系最强.
结论:
- CLN2临床评级表是一个有效的衡量标准,其与PedsQL的相关性得到了支持.
- 运动功能是CLN2疾病中生活质量的关键方面.
- 额外的特定疾病措施可能是必要的,以充分评估生活质量的影响.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

